Medicalgorithmics Sa · GPW:MDG
Medicalgorithmics Sa — Investor Day (February 2024)
36 slides from Medicalgorithmics Sa's investor day presentation, Feb 28, 2024
Slide 1: New Strategy Execution
New Strategy Execution February 2024
Slide 2: About us
About us
Slide 3: Legal disclaimer
Legaldisclaimer This presentation has been prepared by Medicalgorithmics ("the Company") solely for informational purposes. It presents selected data of Medicalgorithmics and should not be construed as investment advice, an offer to acquire or sell any shares or other financial instruments issued on
Slide 4: The Management Board of Medicalgorithmics S.A.
The Management Board of Medicalgorithmics S.A. MACIEJ GAMROT JAROSŁAW JERZAKOWSKI PRZEMYSŁAW TADLA CFO at Medicalgorithmics S.A. COO, Member of the Management CTO, Member of the Management CFO at Kardiolytics Inc. Board at Medicalgorithmics S.A. Board at Medicalgorithmics S.A. CEO at Kardiolytics In
Slide 5: Medicalgorithmics in numbers
Medicalgorithmics in numbers 8k 767 k The company was founded in 2005 Physicians is actively using our products Diagnostic reports generated by our software in 2022 We employ Our products are used by Customers in 120+ 170 k patients 22 countries RnD engineers
Slide 6: Strategy
Strategy
Slide 7: Group Strategy 2023 - 2026
Group Strategy 2023 - 2026 Business Model: Utilize a flexible approach to offer proprietary PocketECG AI software and hardware on a non-exclusive basis or as standalone products. Integrate proprietary software seamlessly with third-party devices A leading global provider of for enhanced cardiac diag
Slide 8: Business Growth
Business Growth
Slide 9: Our presence in markets with high reimbursement
Our presence in markets with high reimbursement Active in 22 markets. Targeting 500 000 patients a year by end of 2025. United States UK • 28 mln Population with AF: 6 mln SWEDEN • Population with AF*: 1,73 mln1 • Reimbursement: $35 - $804 Population with AF: 305 tys.2 • Reimbursement: €215 Reimburs
Slide 10: USA strategy execution
USA strategy execution Increasing market penetration and seeking for profitable business with multiple distributors and richer offering. BEFORE: NOW: An exclusive agreement with one partner Collaboration with multiple partners and a (IDTF) and one product. wider product portfolio (AI) = growth & div
Slide 11: OUS strategy execution
OUS strategy execution Focus with the new strategy on current OUS markets and new countries with the highest growth potential NORTH AMERICA EMEA APAC Canada UK, Switzerland, Austria, Sweden, Australia, India, Philippines, Indonesia Denmark, Israel Achievements Achievements Achievements • Succesfully
Slide 12: Clinical Trials - a new high margin business for Medicalgorithmics
Clinical Trials - a new high margin business for Medicalgorithmics Cardiac safety studies require near real time AF monitoring technology and reporting service GOAL-HF-01 OATD-01-C-03 Heart Failure Drug Idiopathic Pulmonary Fibrosis Randomized double - blinded, placebo - controlled Randomized double
Slide 13: Summary
Summary We are progressing in achieving independence from our hardware by offering integration of existing software and artificial intelligence algorithms in the global market. Successful integrations with 3rd party HW and software. Global contracts with Livetec and Bittium. We operate non-exclusive
Slide 14: Technology
Technology
Slide 15: A leader in medical technology
A leader in medical technology AI/ML Algorithms Cloud Platforms Research is being conducted on new Currently, work is underway on a algorithms for automatic analysis of proprietary platform for ECG data ECG and CT data analysis and a platform for CT data analysis Colaboration with other Medical soft
Slide 16: Scientific research
Scientific research Scientific research has always been an integral part of the company's research and development activities. Since November 2022, Dr. Linda Johnson, a professor at Lund University, has taken over the supervision of clinical research work conducted in the company. Atrial Fibrillatio
Slide 17: NEW product portfolio for the WHOLE cardiology department
NEW product portfolio for the WHOLE cardiology department Fully leveraging the know-how of combined MDG+KL allows rapid product portfolio expansion December 2022 February 2024 Bittium Faros Patch DMS Patch DeepRhythmAI VCAST algorithms Rhythm Express by PocketECG Arrhythmia VivaQuant Diagnostics Sys
Slide 18: NEW product portfolio for the WHOLE cardiology department
NEW product portfolio for the WHOLE cardiology department Fully leveraging the know-how of combined MDG+KL will by 2025 create a portfolio of technologies covering all stages of the cardiac patient journey Healthy Prevention Diagnostics Treatment Home care living
Slide 19: ECG analysis software
Nagłówek ECG analysis software The PC Client software is a state-of-the-art solution The PC Client software by Medicalgorithmics is a powerful and innovative tool for cardiac monitoring and for cardiac diagnostics utilized by monitoring centers analysis. Some of the key advantages of this software a
Slide 20: DeepRhythmAI Algorithms
DeepRhythmAI Algorithms Medicalgorithmics possesses a unique ECG database comprising over 2.5 billion recorded and verified heartbeats that have been annotated and corrected by certified medical specialists, who have dedicated 450,000 work hours to annotating the data. Such a vast amount of data ena
Slide 21: DeepRhythm Platform
DeepRhythm Platform The Deep Rhythm Platform is a new generation of the PC Client software by Medicalgorithmics, based on the DRAI technology. The Deep Rhythm Platform is designed to provide faster and more accurate ECG analysis, using AI algorithms to detect and classify 26 types of arrhythmias. Th
Slide 22: ECG Analysis workflow
ECG Analysis workflow An appointment in a physician's office for Medicalgorithmics prescribing a 24-hour Holter or long-term ECG monitoring by a physician Patient hook-up. Start of the ECG recording Seamless and quick data Signal analysis is performed transfer to the cloud by AI-based algorithms. EC
Slide 23: VCAST – Autonomous CT analysis
VCAST – Autonomous CT analysis VCAST is cloud-based software with a unique technological advantage of AI algorithms for segmentation and reconstruction of narrowed vessels. It provides personalized, color-coded 3D modelling of coronary arteries along with detailed functional diagnostic information r
Slide 24: VCAST – Autonomous CT analysis
VCAST – Autonomous CT analysis Regular monitoring No CAD Cloud software for autonomous CT analysis DICOM Data Pharmacotherapy Stenosis <50% Computed Tomography Invasive therapy Stenosis >50% CAD – Coronary Artery Disease
Slide 25: Main directions of current research and development work
Main directions of current research and development work Research on the next generation of AI/ML Development of cloud platforms for ECG algorithms for ECG and CT image analysis and CT data analysis Development of software for ECG and CT Development of middleware software data analysis centers enabl
Slide 26: Summary
Summary
Slide 27: Summary of the strategy execution
Summary of the strategy execution Successfully validated new strategy, new prospects in the sales pipeline at various stages. BUSINESS DEVELOPMENT Goal to secure 2 new clients per quarter in 2024. NEW CONTRACTS IN Signed 3 contracts with new IDTFs: two featuring AI software and one offering a THE US
Slide 28: MDG Value Creation: Strategic Transformation Driving Growth and Value
MDG Value Creation: Strategic Transformation Driving Growth and Value 1. Restructuring: ▪ Sold US subsidiary Medi-Lynx. ▪ Secured Biofund as a 49.9% strategic investor in October 2022. 3 ▪ Increased share price from below 6.0 PLN to 12.5 PLN. 2 2. New Strategy Formulation, 1H 2023: 1 ▪ The new strat
Slide 29: MDG Value Creation Achieving New Strategy Results
MDG Value Creation Achieving New Strategy Results Execution Phase – towards Positive Financials: 1. Scalable Business: aim to onboard at least two new clients each quarter. 2. Sales Recovery Target: Attain monthly sales of Q3'23 figures in the second half of 2024. 3. Profitability: Operating with hi
Slide 30: Thank you!
Thank you! Maciej Gamrot Mateusz Paradowski CFO, Member of Management Board IR m.gamrot@medicalgorithmics.com +48 516 089 279 https://www.medicalgorithmics.pl/ m.paradowski@innervalue.pl
Slide 31: Appendixes
INNOVATIVE SOLLTIONS IN MEDICINE Appendixes
Slide 32: Medicalgorithmics S.A. Group Consolidated P&Ls (extracts)
Medicalgorithmics S.A. Group Consolidated P&Ls (extracts) 000 PLN 2016 2017 2018 2019 2020 2021 2022 1Q23 2Q23 3Q23 Sales revenue 127 921 203 354 199 404 173 870 111 734 120 563 62 719 11 290 9 705 9 566 Consumption of materials and energy (3 328) (6 250) (9 085) (8 303) (8 542) (7 394) (12 354) (75
Slide 33: Medicalgorithmics S.A. Group Consolidated Balance Sheets (extracts)
Medicalgorithmics S.A. Group Consolidated Balance Sheets (extracts) 000 PLN 31.12.2016 31.12.2017 31.12.2018 31.12.2019 31.12.2020 31.12.2021 31.12.2022 30.09.2023 Intangible assets 237 383 196 900 210 454 209 717 201 767 50 571 63 920 70 230 Tangible fixed assets 22 112 17 249 14 685 31 705 23 535
Slide 34: Medicalgorithmics S.A. Group Consolidated Cash Flows (extracts)
Medicalgorithmics S.A. Group Consolidated Cash Flows (extracts) 000 PLN 2016 2017 2018 2019 2020 2021 2022 1-3Q23 Cash flows from operating activities Net profit (loss) 42 004 33 653 18 948 (299) (27 676) (180 638) (30 404) 98 Depreciation of property, plant and equipment 2 932 5 481 4 969 11 061 8
Slide 35: MDG Group structure and shareholders structure
MDG Group structure 100% 100% 100% 97% of shares of shares of shares of shares US Holding India Private Corporation Limited MDG shareholders structure, ownership and voting Biofund Capital Management LLC 42,76% 49,99% PZU OFE Other shareholders 7,25%
Slide 36: Kardiolytics and Biofund
Kardiolytics and Biofund BioFund's mission is to utilize cutting-edge artificial intelligence and advanced technologies to accelerate progress in medicine, provide advanced medical procedures to those who currently lack access to sophisticated care, and thus make the world a better place. prof. dr h